Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck Acquires 40,000 Shares

Biodesix, Inc. (NASDAQ:BDSX) Director Matthew Strobeck bought 40,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were bought at an average cost of $1.40 per share, with a total value of $56,000.00. Following the purchase, the director now directly owns 2,606,879 shares in the company, valued at approximately $3,649,630.60. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Biodesix Price Performance

Shares of BDSX stock opened at $1.37 on Friday. Biodesix, Inc. has a 12 month low of $1.15 and a 12 month high of $2.21. The company has a market capitalization of $199.29 million, a P/E ratio of -3.41 and a beta of 1.22. The stock has a 50 day moving average of $1.68 and a two-hundred day moving average of $1.61. The company has a current ratio of 3.40, a quick ratio of 3.28 and a debt-to-equity ratio of 1.30.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $18.15 million during the quarter, compared to analysts’ expectations of $18.45 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. During the same period last year, the business earned ($0.12) earnings per share. As a group, equities analysts expect that Biodesix, Inc. will post -0.36 EPS for the current year.

Institutional Investors Weigh In On Biodesix

A number of institutional investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC boosted its holdings in shares of Biodesix by 74.0% in the 2nd quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock worth $8,843,000 after acquiring an additional 2,458,727 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Biodesix during the 2nd quarter worth about $3,326,000. Farallon Capital Management LLC bought a new stake in Biodesix during the 2nd quarter worth about $2,874,000. Essex Investment Management Co. LLC grew its holdings in Biodesix by 1.4% during the 1st quarter. Essex Investment Management Co. LLC now owns 925,614 shares of the company’s stock worth $1,324,000 after acquiring an additional 12,669 shares during the last quarter. Finally, Perkins Capital Management Inc. increased its position in Biodesix by 74.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after acquiring an additional 310,000 shares in the last quarter. 20.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Craig Hallum began coverage on Biodesix in a research report on Friday, July 26th. They set a “buy” rating and a $3.00 price objective for the company. Scotiabank initiated coverage on shares of Biodesix in a research note on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Biodesix currently has an average rating of “Buy” and a consensus price target of $3.06.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.